Please find attached.

IGL/SE/2026-27/36 12th August, 2026 The Manager (Listing) The Manager (Listing) BSE Limited National Stock Exchange of India Limited 1st Floor, New Trading Ring, Exchange Plaza, C-1, Block G, Rotunda Building, P.J. Towers, Bandra Kurla Complex, Dalal Street, Bandra (East), Mumbai – 400 001 Mumbai- 400 051 Scrip Code: 500201 Symbol: INDIAGLYCO Dear Sirs, Sub: Outcome of the Board Meeting held on 12th August, 2026 Further to our letter no. IGL/SE/2026-27/34 dated 5th August, 2026 and pursuant to Regulation 30 and Schedule Ill of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company in its meeting held today i.e. 12th August, 2026 has, inter-alia, considered and approved the Unaudited Financial Results (Standalone and Consolidated) of the Company for the first quarter ended 30th June, 2026. A copy of Unaudited Financial Results (Standalone and Consolidated) of the Company for the first quarter ended 30th June, 2026 along with the Limited Review Report of Statutory Auditors thereon are enclosed herewith. The above said Board Meeting commenced at 15:45 Hrs. and concluded at 16:50 Hrs. This is for your information and record. Thanking you, Yours truly, For India Glycols Limited Ankur Jain Head (Legal) & Company Secretary Encl: A/a INDIA GLYCOLS LIMITED Regd. Office ; A-1, Industrial Area, Bazpur Road, Kashipur -244 713, Distt. Udham Singh Nagar (Uttarakhand) Phones: +91 5947 269000/ 269500., Fax: +91 5947 275315/ 269535 Email: compliance.officer@indiaglycols.com, Website: www.indiaglycols.com CIN No.l24111UR1983PLC009097 Statement Of Unaudited Standalone and Consolidated Financia�Results for the Quarter ended June 30, 2026 (�In Crores, except as stated) !>tanaa1one c:onso1aatea Quarter ended Year ended Quarter ended Year ended S.No Particulars 30.06.2026 31.03.2026 30.06.2025 31.03.2026 30.06.2026 31.03.2026 30.06.2025 31.03.2026 (Unaudited) (Audited) (Unaudited) (Audited) (Unaudited) (Audited) (Unaudited) (Audited) (Refer Note-3) (Refer Note-3) 1 Income from operations (a) Revenue from operations 2,986.92 2,361.40 2,503.03 9,826.20 2,988.44 2,360.01 2,503.12 9,826.63 (b) Other income 0.38 39.20 1.40 43.51 0.38 0.62 1.40 4.93 Total income 2,987.30 2,400.60 2,504.43 9,869.71 2,988.82 2,360.63 2,504.52 9,831.56 2 Expenses (a) Cost of materials consumed 678.45 484.66 669.10 2,412.43 678.45 484.66 669.10 2,412.43 (b) Purchase of stock-in-trade 29.11 40.25 44.19 188.46 30.30 38.79 44.34 187.22 (c) Changes in inventories offinished goods, Stock-in Trade (11.33) 83.51 {35.97) 60.92 (11.33) 83.51 {35.97) 62.35 and work-in-progress (d) Excise Duty 1,858.05 1,383.66 1,462.66 5,615.22 1,858.05 1,383.66 1,462.66 5,615.22 (e) Employee benefits expense 37.02 33.68 30.60 130.69 37.53 34.21 31.06 132.61 (f) Finance Costs 25.18 26.41 44.68 167.18 25.18 26.41 44.68 167.18 (g) Depreciation and amortisation expense 42.48 41.23 34.45 155.38 42.48 41.23 34.45 155.38 (h) Power and fuel 115.42 87.69 91.53 400.50 115.42 87.69 91.53 400.50 (i) Other Expenses 110.28 83.73 93.06 371.40 110.46 80.99 90.76 367.05 Total Expenses 2,884.66 2,264.82 2,434.30 9,502.18 2,886.54 2,261.15 2,432.61 9,499.94 Profit Before Interest, Depreciation and Tax (EBITDA) 170.30 203.42 149.26 690.09 169.94 167.12 151.04 654.18 3 Profit/ (Loss) from operations before exceptional items and tax (1-2) 102.64 135.78 70.13 367.53 102.28 99.48 71.91 331.62 4 Exceotional Items - - - 0.83 - - - 0.83 5 Profit I (Loss) before Tax (3-4) 102.64 135.78 70.13 366.70 102.28 99.48 71.91 330.79 6 Share of net profit/ (loss) of Joint Venture - 20.60 12.98 18.62 46.42 7 Profit/ (Loss) before Tai< (5+6} 102.64 135.78 70.13 366.70 122.88 112.46 90.53 377.21 8 Tax exoense : (a) CurrentTax 13.27 (9.13) 7.57 21.07 13.27 (9.05} 7.57 21.15 l !bl DeferredT ax 12.78 34.63 9.71 63.30 12.78 34.63 � 9.71 63.30 9 Profit/ (Loss) after tax for the period (7-8} 76.59 110.28 52.85 282.33 96.83 86.88 73.25 292.76 10 AO t i i) eC cmo om tp ehr te ath xwe rn i anv toe tI gn c teo e itc l m as ss i tf hie ad t t wo i lP l r no of tit b o er rL eo cs las ssified to Profit or Loss ( 00 .. 02 65 ) ( 01. .5 32 8) . � � ( 00 .. 02 51 ) � ( ,0.3 7) :( 02 ..3 53 9) ::, B (( ii i) I It ne cm os t eh a tat xw ri ell ab te r ge c tl oa s its eif mie sd t ho tP r wo if llit o er rL eo cs ls a ssified to Profit or Loss ) -,� ""' 0.01 NfJ.0: '1 D0 1 0.12 Other Comprehensive Income (Net of Tax) (0.19) (1.14} �l>.A � 1 Ew oE (L 1H .7I 0 ) (/)'( == (Q.15) .80 :-1 10.43) (1.62) 11 Total comprehensive income/ (loss) for the period (9+10) 76.40 109.14 ��::., 280.6J' � ;;" 96.68 \V, '-. 86.08 /�I) 72.82 291.14 ..:.. ,�ro :. . C'�·1 ''''� �/4111 12 Net Profit/ (Loss) attributable to (a) Owners of the Company 96.83 86.88 73.25 292.76 (b) Non Controlling interest - - - - 13 Other Comprehensive Income attributable to (a) Owners of the Company (0.15) (0.80) (0.43) (1.62) (b) Non Controllin� interest - - - - 14 Total Comprehensive Income attributable to (a) Owners of the Company 96.68 86.08 72-.82 291.14 (b) Non Controlling interest - - - 15 Paid-up Eauity Share Caoital (Face value Rs. 5/-each) 33.51 33.51 30.96 33.51 33.51 33.51 30.96 33.51 16 Other Equity 2,503.93 - - - 2,899.27 17 Earnings per equity share (face value of Rs 5/-each) Not annualised (In Rs.) (a) Basic 11.43 17.31 8.53 44.31 14.45 13.64 11.83 45.95 (b) Diluted 11.43 17.31 8.53 44.31 14.45 13.64 11.83 45.95 Unaudited Segment wise Revenue, Results and Assets and Liabilities Standalone Consolidated Quarter ended Year ended Quarter ended Year ended S.No Particulars 30.06.2026 31.03.2026 30.06.2025 31.03.2026 30.06.2026 31.03.2026 30.06.2025 31.03.2026 (Unaudited) (Audited) (Unaudited) (Audited) (Unaudited) (Audited) (Unaudited) (Audited) (Refer Note-3) (Refer Note-3) 1 Segment Revenue -Bio-based Specialities and Performance Chemicals 361.73 302.SS 299.90 1,202.07 363.2S 301.16 299.99 1,202.50 -Potable Spirits 2,218.67 1,690.09 l,80S.06 6,946.43 2,218.67 1,690.09 l,80S.06 6,946.43 -Ennature Biopharma 83.30 63.49 so.so 207.77 83.30 63.49 so.so 207.77 -Bio-Fuel 323.22 30S.27 347.S7 1,469.93 323.22 30S.27 347.57 1,469.93 Total 2,986.92 2,361.40 2,503.03 9,826.20 2,988.44 2,360.01 2,S03.12 9,826.63 2 Segment Results (Profit/ (Loss) before Interest and Tax) -Bio-based Specialities and Performance Chemicals 31.7S 34.47 30.82 138.27 31.39 36.76 32.60 140.9S -Potable Spirits 7S.03 67.78 72.33 284.93 7S.03 67.78 72.33 284.93 -Ennature Biopharma 7.2S 3.01 1.20 7.23 7.2S 3.01 1.20 7.23 -Bio-Fuel 27.03 30.21 22.67 llS.23 27.03 30.21 22.67 llS.23 Total 141.06 135.47 127.02 545.66 140.70 137.76 128.80 548.34 Less/Add: -Interest (Net) 25.18 26.41 44.68 167.18 2S.18 26.41 44.68 167.18 -Exceptional items - - 0.83 - - - 0.83 -Unallocated corporate expenses net of unallocable income 13.24 (26.72) 12.21 10.95 13.24 11.87 12.21 49.54 Profit before share of profit/ (Loss) from joint venture and exceptional items 102.64 135.78 70.13 366.70 102.28 99.48 71.91 330.79 Share of orofit/(loss) of Joint Venture - - 20.60 12.98 18.62 46.42 Profit Before Tax 102.64 135.78 70.13 366.70 122.88 112.46 90.53 377.21 3 Segment assets -Bio-based Specialities and Performance Chemicals 3,514.26 3,595.99 3,435.48 3,595.99 3,518.34 3,600.59 3,438.79 3,600.59 -Potable Spirits 632.16 596.60 �,,,,111'60!n0l 1 ff. 596.60 632.16 �596.60 601.32 596.60 -Ennature Biopharma 417.28 426.4 �� ��� ���� Y/% '\ 426.42 417.28 451.50 426.42 ti ano la- lF lou ce al 61 ,, 15 43 .. .0 1156 61 ,, 14 272 69 #, 2 , . f ,.5.81 304 8.. .0 2 71 . \cf ,Cl - n. ,4 �" 72 679 ... 119 256 61 ,, 545 653 268 ... 70 4 l("'t"/ 6,522.;as 9� L'. ,; \. 61 ,, 252 4404 75 ... 1005 76 61 ,, 54 939 586 % %q. -? � � '0 ,/ 11..(: 11... '�.. ';-, ·E " •J .: ;·\ ;::' ;\ ,;�O \\' 1.� \· ,\. °r ,,..;.�� � '/ --* <>(rJ 4 Segment liabilities -Bio-based Specialities and Performance Chemicals 577.54 737.05 766.87 737.05 578.26 737.97 767.65 737.97 -Potable Spirits 385.41 326.53 339 [Showing first 8,000 characters — download PDF for full document]